Document:

Exhibit 10.1

 

CHINA BIOLOGIC PRODUCTS, INC.

DIRECTOR AGREEMENT

 

THIS AGREEMENT (The “Agreement”)
is made as of the 7th day of November, 2013 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter
referred to as the “Company”), and Mr. David
Li (hereinafter referred to as the “Director”).

 

BACKGROUND

 

The Board of Directors
of the Company desires to appoint the Director to fill an existing vacancy and to have the Director perform the duties of a director
and the Director desires to be so appointed for such position and to perform the duties required of such position in accordance
with the terms and conditions of this Agreement.

 

AGREEMENT

 

In consideration for
the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged,
the Company and the Director hereby agree as follows:

 

1.DUTIES.
The Company requires that the Director be available to perform the duties of a director customarily related to this function as
may be determined and assigned by the Board of Directors of the Company and as may be required by the Company’s constituent
instruments, including its certificate or articles of incorporation, bylaws and its corporate governance and board committee charters,
each as amended or modified from time to time, and by applicable law, including by the Delaware General Corporation Law (the “DGCL”).
The Director agrees to devote as much time as is necessary to perform completely the duties as the Director of the Company. The
Director will perform such duties described herein in accordance with the general fiduciary duty of directors arising under the
DGCL.

 

2.TERM.
The term of this Agreement shall commence as of the date of the Director’s appointment by the Board of Directors of the Company
and shall continue until the Director’s removal or resignation.

 

3.COMPENSATION. The
Director waives any right to compensation in connection with the services provided hereunder.

 

4.EXPENSES.
The Company will reimburse the Director for pre-approved reasonable business related expenses incurred in good faith in the performance
of the Director’s duties for the Company. Such payments shall be made by the Company upon submission by the Director of a
signed statement itemizing the expenses incurred. Such statement shall be accompanied by sufficient documentary matter to support
the expenditures.

 

5.CONFIDENTIALITY.
The Company and the Director each acknowledge that, in order for the intents and purposes of this Agreement to be accomplished,
the Director shall necessarily be obtaining access to certain confidential information concerning the Company and its affairs,
including, but not limited to business methods, information systems, financial data and strategic plans which are unique assets
of the Company (“Confidential Information”). The Director covenants not to, either directly or indirectly, in
any manner, utilize or disclose to any person, firm, corporation, association or other entity any Confidential Information.

 

    	 

    	 

    

 

6.NON-COMPETE.
During the term of this Agreement (the “Restricted Period”), the Director shall not, directly or indirectly,
(i) in any manner whatsoever engage in any capacity with any business competitive with the Company’s current lines of business
or any business then engaged in by the Company, any of its subsidiaries or any of its affiliates (the “Company's Business”)
for the Director’s own benefit or for the benefit of any person or entity other than the Company or any subsidiary or affiliate;
or (ii) have any interest as owner, sole proprietor, shareholder, partner, lender, director, officer, manager, employee, consultant,
agent or otherwise in any business competitive with the Company's Business; provided, however, that (x) this Clause
6 shall not be deemed to prohibit any investment activities of Warburg Pincus LLC and its affiliated funds and the Director’s
activities in connection therewith, provided further that the Director cannot act as a director in any company competing with the
Company’s Business without the Company’s written consent, and (y) the Director may hold, directly or indirectly, solely
as an investment, not more than two percent (2%) of the outstanding securities of any person or entity which are listed on any
national securities exchange or regularly traded in the over-the-counter market notwithstanding the fact that such person or entity
is engaged in a business competitive with the Company's Business.

 

7.TERMINATION.
With or without cause, the Company and the Director may each terminate this Agreement at any time upon ten (10) days written notice,
and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination.
Nothing contained herein or omitted herefrom shall prevent the shareholder(s) of the Company from removing the Director with immediate
effect at any time for any reason.

 

8.INDEMNIFICATION.
The Company shall indemnify, defend and hold harmless the Director, to the full extent allowed by the law of the State of Delaware,
and as provided by, or granted pursuant to, any charter provision, bylaw provision, agreement (including, without limitation, the
Indemnification Agreement executed herewith), vote of stockholders or disinterested directors or otherwise, both as to action in
the Director’s official capacity and as to action in another capacity while holding such office. The Company and the Director
are executing the Indemnification Agreement in the form attached hereto as Exhibit A.

 

9.EFFECT
OF WAIVER. The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed
as a waiver of any subsequent breach thereof.

 

10.NOTICE. Any and
all notices referred to herein shall be sufficient if furnished in writing at the addresses specified on the signature page hereto
or, if to the Company, to the Company’s address as specified in filings made by the Company with the U.S. Securities and
Exchange Commission and if by fax to +8610 6598 3222.

 

    	 

    	 

    

 

11.GOVERNING
LAW. This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be determined by, the
laws of the State of New York without reference to that state’s conflicts of laws principles.

 

12.ASSIGNMENT.
The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder
shall inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of the
Director under this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without
the prior written consent of the Company.

 

13.MISCELLANEOUS.
If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such
invalidity or illegality, the remaining terms and provisions of the this Agreement shall remain in full force and effect in the
same manner as if the invalid or illegal provision had not been contained herein.

 

14.ARTICLE
HEADINGS. The article headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.

 

15.COUNTERPARTS.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument.
Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes.

 

16.ENTIRE
AGREEMENT. Except as provided elsewhere herein, this Agreement sets forth the entire agreement of the parties with respect
to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or
warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect to
such subject matter.

 

 

[Signature Page Follows]

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Director Agreement to be duly executed and signed as of the day and year first above written.

 

 

	 	CHINA BIOLOGIC PRODUCTS, INC.
	 	 	 
	 	 	 
	 	By:	/s/ David Gao__________
	 	Name:	David Gao
	 	Title:  	Chairman & Chief Executive Officer
	 	 	 
	 	 	 
	 	 	 
	 	DIRECTOR
	 	 	 
	 	 	 
	 	By:	/s/ David Li____________
	 	Name: 	David Li
	 	 	 
	 	Address:	 

 

    	 

    	 

    

 

 

 

EXHIBIT A

 

Form of Indemnification Agreement

 

(See Attached)Exhibit 10.1
   
 SECOND AMENDMENT OF
 LEASE AGREEMENT
   
 THIS AGREEMENT is executed in duplicate and effective this 7th day of July, 2013, by and between PURDUE RESEARCH FOUNDATION , an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 25), (“PRF”), and ENDOCYTE (“COMPANY”). In consideration of their mutual promises contained in this Amendment, the parties agree as follows:
  
 WHEREAS, the parties hereto have entered into a Lease Agreement dated January 30, 2013, with a First Amendment of Lease Agreement dated May 17, 2013, between PRF and COMPANY for certain premises at the Purdue Technology Center located at 3000 Kent Avenue, West Lafayette, Indiana; and
  
 WHEREAS, the parties wish to amend provisions of the agreement:
  
 NOW, THEREFORE, IN CONSIDERATION OF the mutual promises and covenants herein, it is agreed between the parties hereto as follows:
   
    	   
 	  1.
 	 The Description of the Lease Premises shall read as follows:
 
	   
 	   
 	   
 
	   
 	   
 	 24,211 square feet in Suites A1-100, A1-200, B1-008, B1-200, B1-201, B1-202, B1-203, B1-300, B1-400, B1-500, A2-100, A2-300, B2-300, B2-400, B2-500, B2-603, B2-700, B2-900, C1-201 and C1-202 (the “Leased Property”) located in the PURDUE TECHNOLOGY CENTER at 3000 Kent Avenue, West Lafayette, Indiana (the “Building”) in the Purdue Research Park (the “Park”). The Leased Property is more particularly shown on EXHIBIT A, attached to this Lease and made a part of this lease by this reference.
 
	   
 	   
 	   
 
	   
 	  2.
 	 The Monthly Rent Installment shall increase to Forty Seven Thousand Eight Hundred Ninety-Six and 35/100 Dollars ($47,896.35).
 
	   
 	   
 	   
 
	   
 	  3.
 	 It is further agreed that all of the terms and conditions of said aforementioned Lease Agreement dated January 30, 2013, with a First Amendment of Lease Agreement dated May 17, 2013, except as hereby amended, are hereby affirmed and shall remain in full force and effect during the remainder of the term thereof.
 

 
  
 WITNESS the signatures and seal of the above parties the day and year first above written.
   
   	 PURDUE RESEARCH FOUNDATION
 	  
 	 ENDOCYTE
 
	  
 	  
 	  
 	  
 
	 By:
 	 /s/ David L. Hodde
 	  
 	 By:
 	 /s/ Michael A. Sherman
 
	  
 	 David L. Hodde
 	   
 	  
 	 Mike Sherman
 
	  
 	 Assistant Vice President
 	  
 	  
 	 Chief Financial Officer
 
	  
 	 Director of Real Estate and Physical Facilities
 	  
 	  
 	  
 
	  
 	  
 	  
 	  
 	  
 
	  
 	  
 	  
 	 By:
 	 /s/ P. Ron Ellis
 
	  
 	  
 	  
 	  
 	 P. Ron Ellis
 
	  
 	   
 	  
 	  
 	 President/CEO
 

 
  
   
  
   
 
  
 EXHIBIT A
 LEASED PREMISES 
  
   	  Unit A1-200
 	  Office Space
 	 9,131 square feet
 
	  Unit B1-008
 	  Office Space
 	 80 square feet
 
	  Unit B1-200
 	  Office Space
 	 168 square feet
 
	  Unit B1-201
 	  Office Space
 	 230 square feet
 
	  Unit B1-202
 	  Office Space
 	 224 square feet
 
	  Unit B1-203
 	  Office Space
 	 363 square feet
 
	  Unit B1-300
 	  Office Space
 	 906 square feet
 
	  Unit B1-400
 	  Office Space
 	  (included in A1-200)
 
	  Unit A2-101
 	  Office Space
 	 253 square feet
 
	  Unit A2-104
 	  Office Space
 	 216 square feet
 
	  Unit A2-105
 	  Office Space
 	 161 square feet
 
	  Unit A2-108
 	  Office Space
 	 215 square feet
 
	  Unit A2-301
 	  Office Space
 	 325 square feet
 
	  Unit A2-304
 	  Office Space
 	 216 square feet
 
	  Unit A2-305
 	  Office Space
 	 161 square feet
 
	  Unit B2-300
 	  Office Space
 	 149 square feet
 
	  Unit B2-400
 	  Office Space
 	 1,513 square feet
 
	  Unit B2-500
 	  Office Space
 	 148 square feet
 
	  Unit B2-603
 	  Office Space
 	 253 square feet
 
	  Unit B2-700
 	  Office Space
 	 148 square feet
 
	  Unit B2-900
 	  Office Space
 	 149 square feet
 
	  Unit C1-201
 	  Office Space
 	 324 square feet
 
	  Unit C1-202
 	  Office Space
 	 191 square feet
 
	   
 	   
 	   
 
	  
 	 Total Office Space
 	  15,524 square feet
 
	  
 	  
 	  
 
	  Unit A1-100
 	  Lab Space
 	 4,069 square feet
 
	  Unit B1-500
 	  Lab Space
 	 690 square feet
 
	  Unit A2-102
 	  Lab Space
 	 367 square feet
 
	  Unit A2-103
 	  Lab Space
 	 325 square feet
 
	  Unit A2-106
 	  Lab Space
 	 495 square feet
 
	  Unit A2-107
 	  Lab Space
 	 477 square feet
 
	  Unit A2-302
 	  Lab Space
 	 339 square feet
 
	  Unit A2-303
 	  Lab Space
 	 409 square feet
 
	  Unit B2-300
 	  Lab Space
 	 379 square feet
 
	  Unit B2-500
 	  Lab Space
 	 380 square feet
 
	  Unit B2-700
 	  Lab Space
 	 378 square feet
 
	  Unit B2-900
 	  Lab Space
 	 379 square feet
 
	   
 	   
 	   
 
	  
 	 Total Lab Space
 	  8,687 square feet

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]